FDA Approves Supplement for Deutetrabenazine by Aurobindo Pharma
The FDA has approved a supplemental application for deutetrabenazine submitted by Aurobindo Pharma.
Indication
Clinical and regulatory intelligence for Movement Disorders with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.